Monday, October 5, 2026

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· April 9, 2026

Tesla vs. Ford: Don’t Buy Either Stock Until You Read This

View original at finance.yahoo.com

“Cash Position $44.059B (+173% YoY) $23.356B (+11.94% YoY)”

Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Ford is targeting 8% adjusted EBIT margin by 2029
60% confidence
The analyst who called NVIDIA in 2010 just named his top 10 AI stocks
60% confidence

Data points we hold from this source

Ford Motor Company · net income	-11.10 USD
Ford Motor Company · cash growth	11.94 percent
Ford Motor Company · cash	23.356 USD
Ford Motor Company · gross profit growth	-17.44 percent

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave

Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,985

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,985 facts checked against source5,340 source documents archived

Query this data → isubstrate.com